832113-96-9

Basic information

• Product Name: METHYL 4-CHLORO-5-METHYL-THIENO[2,3-D]PYRIMIDINE-6-CARBOXYLATE
• Synonyms: METHYL 4-CHLORO-5-METHYL-THIENO[2,3-D]PYRIMIDINE-6-CARBOXYLATE;4-CHLORO-5-METHYL-THIENO[2,3-D]PYRIMIDINE-6-CARBOXYLIC ACID METHYL ESTER
• CAS NO: 832113-96-9
• Molecular Formula: C₉H₇ClN₂O₂S
• Molecular Weight: 242.68
• Mol File: 832113-96-9.mol

Chemical Properties

• Boiling Point: 363.3±37.0 °C(Predicted)
• Appearance: /
• Density: 1.465±0.06 g/cm3(Predicted)
• PKA: -0.01±0.40(Predicted)
• CAS DataBase Reference: METHYL 4-CHLORO-5-METHYL-THIENO[2,3-D]PYRIMIDINE-6-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 4-CHLORO-5-METHYL-THIENO[2,3-D]PYRIMIDINE-6-CARBOXYLATE(832113-96-9)
• EPA Substance Registry System: METHYL 4-CHLORO-5-METHYL-THIENO[2,3-D]PYRIMIDINE-6-CARBOXYLATE(832113-96-9)

Safety Data

• Hazardous Substances Data: 832113-96-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
METHYL 4-CHLORO-5-METHYL-THIENO[2,3-D]PYRIMIDINE-6-CARBOXYLATE is used as a reactant in the synthesis of enzyme inhibitors for the development of pharmaceuticals targeting specific diseases and conditions. Its role in the synthesis process is crucial for creating effective and targeted treatments.
Used in Biochemical Research:
In addition to its pharmaceutical applications, METHYL 4-CHLORO-5-METHYL-THIENO[2,3-D]PYRIMIDINE-6-CARBOXYLATE is also utilized in biochemical research as a reactant for the synthesis of enzyme inhibitors. This allows researchers to study the mechanisms of action and potential applications of these inhibitors in understanding and treating various biological processes and diseases.

InChI:InChI=1S/C9H7ClN2O2S/c1-4-5-7(10)11-3-12-8(5)15-6(4)9(13)14-2/h3H,1-2H3

Relevant articles and documents

Discovery of 4-(dihydropyridinon-3-yl)amino-5-methylthieno[2,3-d[pyrimidine derivatives as potent Mnk inhibitors: Synthesis, structure-activity relationship analysis and biological evaluation

Phosphorylation of the eukaryotic initiation factor 4E (eIF4E) by mitogen-activated protein kinase (MAPK)-interacting kinases (Mnks) is essential for oncogenesis but unnecessary for normal development. Thus, pharmacological inhibition of Mnks may offer an effective and non-toxic anti-cancer therapeutic strategy. Herein, we report the discovery of 4-(dihydropyridinon-3-yl)amino-5-methylthieno[2,3-d]pyrimidine derivatives as potent Mnk inhibitors. Docking study of 7a in Mnk2 suggests that the compound is stabilised in the ATP binding site through multiple hydrogen bonds and hydrophobic interaction. Cellular mechanistic studies on MV-4-11 cells with leads 7a, 8e and 8f reveal that they are able to down-regulate the phosphorylated eIF4E, Mcl-1 and cyclin D1, and induce apoptosis.

An integrated approach for discovery of highly potent and selective Mnk inhibitors: Screening, synthesis and SAR analysis

Deregulation of protein synthesis is a common event in cancer. As MAPK-interacting kinases (Mnks) play critical roles in regulation of protein synthesis, they have emerged as novel anti-cancer targets. Mnks phosphorylate eukaryotic initiation factor 4E (eIF4E) and promote eIF4E-mediated oncogenic activity. Given that the kinase activity of Mnks is essential for oncogenesis but is dispensable for normal development, the discovery of potent and selective pharmacological Mnk inhibitors provides pharmacological target validation and offers a new strategy for cancer treatment. Herein, comprehensive in silico screening approaches were deployed, and three thieno[2,3-d]pyrimidine and pyrazolo[3,4-d]pyrimidine derivatives were identified as hit compounds. Further chemical modification of thieno[2,3-d]pyrimidine derivative 3 has given rise to a series of highly potent Mnk2 inhibitors that could be potential leads for the treatment of acute myeloid leukemia.